Liquidia's YUTREPIA Generates $148.3 Million in Net Sales, Supports Pipeline Expansion

Liquidia Corporation reported preliminary 2025 results showing YUTREPIA generated $148.3 million in net product sales, including $90.1 million in Q4, with over 2,800 unique prescriptions and positive cash flow. The company expanded its field sales team and advanced additional clinical programs, pushing to deepen YUTREPIA's adoption and build its pipeline with candidate L606. This strengthens the commercial pillar of the thesis but raises the bar on consistent performance.